GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (FRA:GBM) » Definitions » Cyclically Adjusted PS Ratio

Inovio Pharmaceuticals (FRA:GBM) Cyclically Adjusted PS Ratio : (As of Jun. 14, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Inovio Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Inovio Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Inovio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.84 27.98 16.59 5.05 1.81

Inovio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.65 1.44 1.35 1.81 -

Competitive Comparison of Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Inovio Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Inovio Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Inovio Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Inovio Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.555 100.560 0.727
201409 0.283 100.428 0.371
201412 0.393 99.070 0.523
201503 0.941 99.621 1.245
201506 0.833 100.684 1.090
201509 3.496 100.392 4.589
201512 0.903 99.792 1.192
201603 1.210 100.470 1.587
201606 0.908 101.688 1.177
201609 1.817 101.861 2.351
201612 1.308 101.863 1.692
201703 1.567 102.862 2.007
201706 2.891 103.349 3.686
201709 0.306 104.136 0.387
201712 0.984 104.011 1.247
201803 0.165 105.290 0.207
201806 2.753 106.317 3.412
201809 0.223 106.507 0.276
201812 0.275 105.998 0.342
201903 0.308 107.251 0.378
201906 0.015 108.070 0.018
201909 0.092 108.329 0.112
201912 0.030 108.420 0.036
202003 0.116 108.902 0.140
202006 0.018 108.767 0.022
202009 0.014 109.815 0.017
202012 0.315 109.897 0.378
202103 0.018 111.754 0.021
202106 0.013 114.631 0.015
202109 0.014 115.734 0.016
202112 0.042 117.630 0.047
202203 0.010 121.301 0.011
202206 0.038 125.017 0.040
202209 0.445 125.227 0.468
202212 0.006 125.222 0.006
202303 0.005 127.348 0.005
202306 0.009 128.729 0.009
202309 0.016 129.860 0.016
202312 0.004 129.419 0.004
202403 0.000 131.776 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Inovio Pharmaceuticals  (FRA:GBM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Inovio Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Inovio Pharmaceuticals (FRA:GBM) Business Description

Traded in Other Exchanges
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Inovio Pharmaceuticals (FRA:GBM) Headlines

No Headlines